---
schema_version: "secwatch.filing_event.v1"
accession: "0001740797-24-000056"
form_type: "8-K"
ticker: "AVAI"
cik: "0001740797"
company_name: "AVAI BIO, INC."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:04:10.791855+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Avant to fund up to $20M, forms 50/50 JV with Ainnova for retina AI tech

## Summary
- Avant contributes up to $20M in capital over 12 months to new JV 'Ai-Nova Acquisition Corp'.
- Ainnova contributes Vision AI technology portfolio for retinal disease detection and scanning.
- Ownership split 50% Avant, 50% Ainnova; JV to issue 2,000,000 shares.
- Profit distribution: first to Ainnova for contributed business value, then Avant for capital, then pro-rata.
- Territories include US, Canada, Europe; JV to seek third-party licensing and strategic transactions.

## SEC filing metadata
- accession: 0001740797-24-000056
- form_type: 8-K
- ticker: AVAI
- cik: 0001740797
- company_name: AVAI BIO, INC.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740797/000174079724000056/0001740797-24-000056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740797/000174079724000056/report8k_avai.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001740797-24-000056
- JSON: https://secwatch.observer/filing/0001740797-24-000056.json
- Plain text: https://secwatch.observer/filing/0001740797-24-000056.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.